Correspondence Appropriate Comparators for Alternate Dosing Strategies

To the Editor—Clinical studies remain the gold standard for validation of phar-macokinetic-pharmacodynamic models that attempt to define the complex inter-actions among antibiotics, infecting or-ganisms, and the human host. Compari-son with a currently accepted and proven therapy is an important consideration. Prosepective, randomized, controlled tri-als of piperacillin-tazobactam for the treat-ment of nosocomial pneumonia have included dosing regimens of 4.5 g admin-istered every 6 h and 3.375 g administered every 4 h with concomitant aminoglyco-side therapy [1, 2]. We are unaware of an